Shop Tirzepatide

References

Sources, in full.

Every quantitative claim on this site cites a peer-reviewed publication, FDA label, or registered clinical trial. The full list is below, with DOIs and direct links.

How to read this list

Citations are numbered 1 through 19. Inline markers on other pages — like [3] — correspond to the numbered entries below. Where a digital object identifier (DOI) exists, it is the canonical link; where a PubMed or PMC URL is more directly readable, it is provided as well.

The trial-program references are organized roughly in the order they appear in the research summary: SURMOUNT-1 first (the headline weight-loss result), then SURPASS-1 through -5 (type 2 diabetes), then SURMOUNT-2 through -4 (obesity), then SURMOUNT-OSA, SUMMIT, and SYNERGY-NASH (sleep apnea, HFpEF, MASH), then SURPASS-CVOT and the SURMOUNT-1 prediabetes extension, then mechanism, pharmacokinetic, safety, blood pressure, and prevention publications.

All references were retrieved from primary peer-reviewed journals (New England Journal of Medicine, The Lancet, JAMA, Nature Medicine, JCI Insight, Diabetes Obesity and Metabolism, Cardiovascular Diabetology, Journal of Endocrinological Investigation, CPT: Pharmacometrics & Systems Pharmacology). The FDA prescribing information is the source for labeled dosing and the boxed warning.

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022. ↗
  2. Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021. ↗
  3. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021. ↗
  4. Ludvik B, Giorgino F, Jodar E, et al. Tirzepatide versus insulin degludec in type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 2021. ↗
  5. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021. ↗
  6. Dahl D, Onishi Y, Norwood P, et al. Effect of Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022. ↗
  7. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2023. ↗
  8. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine. 2023. ↗
  9. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. ↗
  10. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. 2024. ↗
  11. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2024. ↗
  12. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. 2024. ↗
  13. Bhatt DL, Pratley RE, Cosentino F, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine. 2025. ↗
  14. Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. ↗
  15. Furihata K, Mimura H, Urva S, et al. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: Pharmacometrics & Systems Pharmacology. 2024. ↗
  16. Rubino DM, Aronne LJ, Wadden TA, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes, Obesity and Metabolism. 2025. ↗
  17. Caruso I, Di Gioia L, Di Molfetta S, et al. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Journal of Endocrinological Investigation. 2024. ↗
  18. de Boer IH, Khunti K, Sadusky T, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovascular Diabetology. 2023. ↗
  19. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2025. ↗
  20. Safwan M, et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Ann Saudi Med. 2025. ↗
  21. Shen P, et al. Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis. PLoS One. 2026. ↗
  22. Mishra R, et al. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-analysis. Cureus. 2023. ↗
  23. U.S. Food and Drug Administration. Tirzepatide injection prescribing information (FDA label, type 2 diabetes indication). FDA Drugs@FDA. 2022. ↗
  24. Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. ↗
  25. Gong J, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis. J Diabetes Investig. 2025. ↗
  26. Nassar M, et al. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis. Diabetes Metab Syndr. 2024. ↗
  27. Jalleh RJ, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024. ↗
  28. Urva S, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020. ↗
  29. Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. ↗
  30. Batsis JA, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Ann Intern Med. 2026. ↗
  31. Berg S, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev. 2025. ↗
  32. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. ↗
  33. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. ↗
  34. U.S. Food and Drug Administration. FDA approval for chronic weight management (tirzepatide) — press announcement and label record. FDA News and Events. 2023. ↗
  35. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. ↗
  36. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025. ↗
  37. Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. ↗